EMERGENT BIOSOLUTIONS INC. Deferred Federal Income Tax Expense (Benefit)
EMERGENT BIOSOLUTIONS INC. (EBS) reported Deferred Federal Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-27
- EMERGENT BIOSOLUTIONS INC. deferred federal income tax expense (benefit) for fiscal 2025 was $0.00.
- EMERGENT BIOSOLUTIONS INC. deferred federal income tax expense (benefit) for fiscal 2024 was -$4.40M.
- EMERGENT BIOSOLUTIONS INC. deferred federal income tax expense (benefit) for fiscal 2023 was -$2.00M.
- EMERGENT BIOSOLUTIONS INC. deferred federal income tax expense (benefit) for fiscal 2022 was -$37.70M, a 201.62% decline from fiscal 2021.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-27 | |
| 2024-12-31 | -$4.40M 10-K · filed 2026-02-27 | |
| 2023-12-31 | -$2.00M 10-K · filed 2026-02-27 | |
| 2022-12-31 | -$37.70M 10-K · filed 2025-03-04 | -$39.00M 10-K · filed 2023-03-01 |
| 2021-12-31 | $37.10M 10-K · filed 2024-03-08 | $38.00M 10-K · filed 2022-02-25 |
| 2020-12-31 | $500.00K 10-K/A · filed 2023-12-11 | $1.10M 10-K · filed 2021-02-19 |
| 2019-12-31 | $1.90M 10-K · filed 2022-02-25 | |
| 2018-12-31 | $7.50M 10-K · filed 2021-02-19 | |
| 2017-12-31 | -$6.00M 10-K · filed 2020-02-25 | -$6.04M 10-K · filed 2018-02-23 |
| 2016-12-31 | $10.00M 10-K · filed 2019-02-22 | $9.98M 10-K · filed 2017-02-28 |
| 2015-12-31 | -$119.00K 10-K · filed 2018-02-23 | $7.80M 10-K · filed 2016-02-29 |
| 2014-12-31 | $3.33M 10-K · filed 2017-02-28 | $7.69M 10-K · filed 2015-03-09 |
| 2013-12-31 | $12.68M 10-K · filed 2016-02-29 | |
| 2012-12-31 | $3.76M 10-K · filed 2015-03-09 | |
| 2011-12-31 | $19.05M 10-K · filed 2014-03-10 | |
| 2010-12-31 | $10.00M 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |